Natera and TransCode Therapeutics to Collaborate on Ph 2a Trial of TTX-MC138 in CRC
“Identifying recurrence of colorectal cancer before it becomes clinically apparent, when it is potentially much easier to treat, is one of the central challenges in developing breakthrough therapies that help to answer unmet medical needs for this setting,” said Philippe P. Calais, PharmD, Ph.D., chairman and CEO, TransCode Therapeutics. “Leveraging one of the most established MRD testing footprints will help us identify high-risk patients faster and potentially intervene earlier, advancing a new treatment paradigm focused on addressing cancer at the molecular residual disease stage before recurrence becomes clinically apparent.”
Share:
More News
“The improvement in progression-free survival is a defining moment for RYZ101 and for the patients we built this program around — people with advanced GEP-NETs whose cancer has progressed after Lu177-based therapy and who have few remaining options,” said Amreen Husain, MD, chief medical officer of RayzeBio. “This is the
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated, “The FDA’s decision to grant Fast Track Designation just nine days after submission is an encouraging milestone for opamtistomig and our first-line BTC program. We appreciate the FDA’s engagement and its recommendation to initiate discussions on the U.S. registration strategy
“PI3Kα is one of the most important, well-validated, and heavily pursued disease drivers in oncology, but its therapeutic potential has been constrained by wild-type PI3Kα-mediated toxicity and incomplete coverage of clinically relevant mutations,” said Rob Kania, Ph.D., Chief Executive Officer of KymaThera. “Our drug design objective from the outset was
“RAS G12D is the most common RAS variant in PDAC,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “In preclinical studies, the combination of RAS(ON) multi-selective and G12D-selective inhibitors achieved deeper and more sustained suppression of RAS signaling than either agent alone, accompanied by greater tumor control. Likewise,